EGFR and non-small cell lung carcinoma: A greater number of NSCLC patients will have data regarding their cancer’s genomic details as EGFR TKIs become more widely accepted for adjuvant and potentially neoadjuvant therapy, which will also enable greater sample sizes and confidence in results.